Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Leukemia & Lymphoma|October 6, 2007
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftmentHeather Oakervee, Rakesh Popat, Jamie D Cavenagh
Expert Opinion on Pharmacotherapy|June 30, 2006
Bortezomib for multiple myelomaRakesh Popat, Simon Joel, Heather Oakervee, et al.
British Journal of Haematology|February 13, 2009
Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centreJane M Stevens, Finlay Macdougall, Michael Jenner, et al.
Heart (British Cardiac Society)|April 6, 2021
Optimising cardiovascular care of patients with multiple myelomaMarta Fontes Oliveira, Willeke R Naaktgeboren, Alina Hua, et al.
British Journal of Haematology|May 31, 2013
Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletionJeff K Davies, David Taussig, Heather Oakervee, et al.
Journal of Medical Case Reports|December 11, 2008
Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case reportKolitha Basnayake, Colin Hutchison, Dia Kamel, et al.
Hematology (Amsterdam, Netherlands)|April 25, 2007
Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapyBhawna Sirohi, Ray Powles, Jamie Cavanagh, et al.
British Journal of Haematology|October 28, 2017
Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasiaJeff K Davies, Sandra Hassan, Shah-Jalal Sarker, et al.
The Lancet. Haematology|November 16, 2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Sarah R Brown, Louise Flanagan, et al.
British Journal of Haematology|February 3, 2009
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myelomaRakesh Popat, Heather Oakervee, Catherine Williams, et al.
Pageof 2